FRI0416 CHARACTERISTICS AND CAPILLAROSCOPIC FINDINGS OF SYSTEMIC SCLEROSIS PATIENTS WITH SEVERE PERIPHERAL VASCULAR INVOLVEMENT RECEIVING SPECIFIC VASODILATOR TREATMENT
Y. Yalçınkaya, A.U. Ünal, Z. Ertürk, U. Gazel, S. Kaymaz, A. Aksoy, P. Atagündüz, N.İnanç, H. Direskeneli. Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey Background: Severity of peripheral vascular involvement (PVI)is known as an important determinig cause of morbidity in sytemic sclerosis (SSc). Different vasodilating agents have been found to reduce severity and contribute to healing of digital ulcers (DU)in SSc.
Objectives: We aimed to evaluate the characteristics and capillaroscopic patterns of the patients with severe PVI under different vasodilator therapeutic regimens. Methods: The patients were grouped as "severe PVI" if score of PVI is ≥2 (PVT=2,digital pitting scars; PVT=3, digital tip ulcerations and PVT=4, digital gangrene; Medsger) and "non-severe PVI" if score of PVI is ≤1 (PVI=0,no Raynaud's; PVI=1, Raynaud's requiring vasodilators). We included patients with severe PVI who received cyclic iloprost and bosentan and/or sildenafil and compared to non-severe PVI. Nail fold video-capillaroscopy (NVC)was assessed qualitatively (Cutalo et al., early, active and late patterns). Results: Severe PVI group more frequently had diffuse cutaneous form, contractures, lung disease, anti-Scl70 positivity and high acute phase response and exposed to immunosuppressives (table-1). Scores of telangiectasia, skin, activity and severity were lower in non-severe group. NVC late pattern was frequent and early pattern was rare in severe PVI groups. Forty-one% (9/22) of patients received second oral agent for PVI.
Monotherapy and combination groups had similar scores (table-2).
Conclusions: NVC late pattern was frequent in severe PVI group with long disease duration, exposed to intensive immunosuppresives and received specific vasodilators for PVI. Disease activity and severity were higher in severe PVI group. One third of the severe group required oral combination therapy for PVI. Monotherapy and combination groups were similar in terms of severity. NVC is a useful method to monitor digital ischemia and severe organ involvement in SSc. Background: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of current best treatments. As the pulmonary vascular disease (PVD) can be well compensated for, more than a half of the pulmonary circulation is impaired before early PAH is detected. Although recent studies focused on molecular basis of the PVD, the underlying mechanisms have not been fully elucidated, especially at the early stage of the disease. Objectives: To detect the subclinical PVD, and to explore the changes in transcriptome of peripheral blood at the early stage of SSc associated PAH. Methods: Total of 74 cases without PAH symptoms (NYHA I) with either Raynaud phenomenon (RP: n=61), skin sclerosis (n=43) or SSc-related autoantibody (anti-RNP: n=10, centromere: n=36, topoisomerase-1: n=2, RNA polymerase III: n=2) were enrolled. To detect the latent PAH, exercise Doppler echocardiography (DE) with Master's two-step stress was carried out. Systolic PAP (sPAP) was determined by maximum velocities of tricuspid regurgitation jets, and exercise induced pulmonary hypertension (exPH) group was segregated from normal response group (exN) with using the definition of a sPAP greater than 40 mm Hg during exercise, or a exercise increase in sPAP by greater than 20 mm Hg 1) . For transcriptome analysis, total RNAs from whole peripheral blood cells were extracted with using PAXgene miRNA kit. After constructing single-stranded, strand-specific libraries, multiplex sequencing was done. After quantifying the expressions of transcripts, differentially expressed genes (DEGs) between exPH and exN group were selected by paired T-test (P<0.05). And then, hierarchical clustering analysis and pathway enrichment analysis (PathVisio) were performed. Results: There were no significant differences between exPH and exN group in the result of total skin score, serum BNP, tests of pulmonary function and thermography after 0°C-stress. Positive SSc-related autoantibody was a risk factor for exPH (odds ratio, 1.41); especially, positive anti-RNP seemed to be prominent (odds ratio, 3.21). Based on the 817 DEGs between exPH and exN group, the hierarchical clustering showed major 4 clusters, and one of them consisted of only cases in exPH group. When we focused on 117 genes reported to be directly implicated in the development of PAH 2) , it is noteworthy that 4 of them including TGF-β induced protein were differentially expressed. Pathway analysis of transcriptome revealed that 22 pathways, such as hypertrophy model, lung fibrosis and Wnt/B-catenin signaling, were differently enriched between exPH and exN group. Conclusions: The paradigm of SSc-PAH management should ideally be aimed at detecting early PVD and starting treatment prior to fulfilling the criteria for PAH. Although detection of early PVD in SSc patients remains a major challenge, exercise DE seemed to be a good, non-invasive method for screening. It is noteworthy that expression changes in some of known PAH-related genes were detected from peripheral blood of exPH patients. It shows the possibility that the therapeutic intervention at early stage of the disease may alter the clinical course. Background: The inflammatory myopathies are a heterogeneous group of connective tissue diseases characterized by muscle weakness and inflammation. Corticosteroids are the standard main treatment for inflammatory myopathies. However, steroid therapy often causes a wide range of side effects. Although immunosuppressive drugs are used as steroid-sparing agents in an effort to prevent disease recurrence, the appropriate duration of steroid use remains unclear. Objectives: We investigated whether steroid therapy can be safely withdrawn in patients with inflammatory myopathies followed in a single center. Methods: We retrospectively reviewed clinical charts of 71 consecutive patients (age 51.9±15.7 y.o., female 69%) who met Bohan and Peter criteria for polymyositis (PM)/dermatomyositis (DM) and modified Sontheimer's criteria for clinically amyopathic dermatomyositis (ADM), respectively. Steroid free remission was defined as a 3-month consecutive period of no disease activity without corticosteroid treatment. Factors associated with steroid free remission were examined. Results: Of 71 identified patients, 29 patients (40%) were DM, 15 patients (21%) were PM, 9 patients (13%) were overlap myositis, and 18 patients (25%) were ADM. Thirty-seven patients (52%) had muscle weakness, 5 patients (7%) had malignancies and 43 patients (61%) had signs of interstitial lung disease. With a mean follow-up of 6.6±5.0 years, 9 patients (13%) died during follow-up period. The remaining 62 patients were treated with corticosteroids alone or in combination with immunosuppressants. Steroid-free remission was achieved in 21 of 62 patients (34%) patients with a mean time to steroid withdrawal of 5.5±4.0 years. Six of 21 patients (29%) relapsed 1.7±1.7 years after steroid withdrawal. There were no differences in onset of age, disease duration, positive ANA, positive Anti Jo-1 antibodies, serum creatine kinase levels, maximum dose of corticosteroids, skin, joint and lung involvement between steroid-free group and non-steroid-free group. Elevated inflammatiory markers were associated with long-term steroid use (p=0.038). Concominant immunosuppressants were more frequently used in non-steroid-free group than steroid-free group (p=0.002). Conclusions: Steroid-free remission might be achieved in some patients with inflammatory myopathies. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4750 
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